Molecular binding can be classified into the following types: •
Non-covalent – no chemical bonds are formed between the two interacting molecules hence the association is fully reversible • Reversible
covalent – a chemical bond is formed, however the
free energy difference separating the noncovalently-bonded reactants from bonded product is near
equilibrium and the
activation barrier is relatively low such that the reverse reaction which cleaves the chemical bond easily occurs • Irreversible covalent – a chemical bond is formed in which the product is
thermodynamically much more stable than the reactants such that the reverse reaction does not take place. Bound molecules are sometimes called a "molecular complex"—the term generally refers to
non-covalent associations. Non-covalent interactions can effectively become irreversible; for example,
tight binding inhibitors of
enzymes can have kinetics that closely resemble irreversible covalent inhibitors. Among the tightest known protein–protein complexes is that between the enzyme
angiogenin and
ribonuclease inhibitor; the dissociation constant for the human proteins is 5×10−16 mol/L. Another biological example is the binding protein
streptavidin, which has extraordinarily high affinity for
biotin (vitamin B7/H,
dissociation constant, Kd ≈10−14 mol/L). In such cases, if the reaction conditions change (e.g., the protein moves into an environment where biotin concentrations are very low, or pH or ionic conditions are altered), the reverse reaction can be promoted. For example, the biotin-streptavidin interaction can be broken by incubating the complex in water at 70 °C, without damaging either molecule. An example of change in local concentration causing dissociation can be found in the
Bohr effect, which describes the dissociation of ligands from
hemoglobin in the lung versus peripheral tissues. and some
pharmaceuticals are
irreversible antagonists that may or may not be covalently bound.
Drug discovery has been through periods when drug candidates that bind covalently to their targets are attractive and then are avoided; the success of
bortezomib made
boron-based covalently binding candidates more attractive in the late 2000s. == Driving force ==